Article

Characterization of a <i>RAD51C</i> -Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

2020-12-26

Abstract excerpt

<h4>ABSTRACT</h4> Acquired PARP inhibitor (PARPi) resistance in BRCA1 - or BRCA2 -mutant ovarian cancer often results from secondary mutations that restore expression of functional protein. RAD51C is a less commonly studied ovarian cancer susceptibility gene whose promoter is sometimes methylated in the tumor, leading to homologous recombination deficiency and PARPi sensitivity. For this study, the PARPi-sensi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7626dde8-0550-52d8-b546-0ce4e1d01a93
DOI: 10.1101/2020.12.25.419978

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Characterization of a <i>RAD51C</i> -Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance DevelopmentDOI 10.1101/2020.12.25.419978Read

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceSemantic proximity Read

Acquired <i>RAD51C</i> promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinomaSemantic proximity Read

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaSemantic proximity Read

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.Semantic proximity Read

Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity Read

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity Read

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Semantic proximity Read

RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.Semantic proximity Read

Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinomaSemantic proximity Read

Mechanisms of PARP inhibitor resistance in ovarian cancerSemantic proximity Read

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOCSemantic proximity Read

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell linesSemantic proximity Read